장기(또는, 영향을 받은 알려진 모든 장기를 명시)에 손상을 일으킴(노출되어도 특정 표적장기 독성을 일으키지 않는다는 결정적인 노출경로가 있다면 노출경로를 기재)
특정 표적장기 독성 - 1회 노출
구분 1
위험
P260, P264, P270, P307+P311, P321,P405, P501
예방조치문구:
P260
분진·흄·가스·미스트·증기·...·스프레이를 흡입하지 마시오.
P261
분진·흄·가스·미스트·증기·...·스프레이의 흡입을 피하시오.
P264
취급 후에는 손을 철저히 씻으시오.
P264
취급 후에는 손을 철저히 씻으시오.
P270
이 제품을 사용할 때에는 먹거나, 마시거나 흡연하지 마시오.
P272
작업장 밖으로 오염된 의복을 반출하지 마시오.
P280
보호장갑/보호의/보안경/안면보호구를 착용하시오.
P301+P312
삼켜서 불편함을 느끼면 의료기관(의사)의 진찰을 받으시오.
P302+P352
피부에 묻으면 다량의 물로 씻으시오.
P307+P311
노출된 경우,독성 물질 센터 또는 의사에게 전화하기
P321
(…) 처치를 하시오.
P330
입을 씻어내시오.
P333+P313
피부자극성 또는 홍반이 나타나면 의학적인 조치·조언를 구하시오.
P363
다시 사용전 오염된 의류는 세척하시오.
P405
밀봉하여 저장하시오.
P501
...에 내용물 / 용기를 폐기 하시오.
리미펜타닐 C화학적 특성, 용도, 생산
용도
Analgesic.
정의
ChEBI: A piperidinecarboxylate ester that is methyl piperidine-4-carboxylate in which the hydrogen attached to the nitrogen is substituted by a 3-methoxy-3-oxopropyl group and the hydrogen at position 4 is substituted the nitrogen of N-propanoy
aniline.
World Health Organization (WHO)
Remifentanil is defined as an opioid narcotic with an addictionforming
and addiction-sustaining liability similar to morphine.
일반 설명
Remifentanil (Ultiva) was designed as a “soft drug.” Softdrugs are designed to undergo metabolism quickly and thushave ultrashort durations of action. In place of the ethylaromatic ring seen on the other piperidine opioids, remifentanilhas an ester group. This ester group is metabolizedby esterases in the blood and tissue to a weaklyactive metabolite (1:300–1:1,000 the potency of remifentanil). The n-octanol/water partition coefficient ofremifentanil is 17.9. The pKa of remifentanil is 7.07, thus itis predominately unionized at physiological pH. Both ofthese properties account for its rapid distribution across theblood-brain barrier (<1 minute). The ester hydrolysis leadsto a quick recovery (5–10 minutes) independent of durationof drug administration, renal, or liver function. The favorablepharmacodynamics of remifentanil have led to its usefor induction and maintenance of surgical anesthesia.
Pharmacology
Remifentanil is a MOP agonist with a similar potency to fentanyl and
approximately 20 times more than alfentanil. It has a rapid blood–brain
equilibration time of just over 1min, with a short context-sensitive half-life of
3–5min, which is unaffected by duration of infusion. This makes it ideally
suited for infusion during anaesthesia and in critical care. It may be titrated
rapidly to achieve the desired effect. Remifentanil is available as a lyophilised
white crystalline powder containing glycine; it should not be administered
via the epidural or intrathecal routes. There may be increased opioid
sensitivity in hepatic disease, resulting in a lower dosage requirement. Other
situations requiring a reduction in dose include haemorrhage and shock and
when administering in elderly patients. The high clearance and low VD imply
that the offset of effect is caused by metabolism rather than redistribution.
Hypothermia, such as may occur in cardiac surgery, may reduce clearance by
up to 20%.
There is some evidence to suggest that acute opioid tolerance and
hyperalgesia may occur, particularly after remifentanil infusions. If high
doses are used without neuromuscular blockade, muscle rigidity may be a
problem, though this is less likely if using a concentration of 100 μgml-1 or
less and an infusion rate of 0.2–0.5μgkg-1 min-1. Bradycardia has also been
reported.